Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ENTX vs EQ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENTX Captures Overall Composite Edge (47.5 HOLD vs 48.6 HOLD), While EQ Leads 3–1 on Growth & Valuation Pillars
ENTX Overall Winner
6-Pillar Tally: ENTX 1 – 3 EQ (2 Tie)
Matrix Metrics: ENTX 4 – 4 EQ
As of Nov 20, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (47.5/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 4–4 (led by Options & Positioning), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. ENTX trades at $3.31 (N/M Forward P/E, 0.0% operating margin) versus EQ at $1.06 (1.5x Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-100.0% vs. -52.3% YoY).
- Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ENTX vs EQ
ENTX
Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
$3.31
+0.76% 1D
Market Cap
$571.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.92β · 53% Vol
Unified Composite Score
47.5
HOLD
Tech 52.0
Fund 49.0
Flow 72.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
EQ
Equillium, Inc. Common Stock
$1.06
-5.36% 1D
Market Cap
$92.2M
TTM Revenue
$4.4M
Forward P/E
1.5x
Beta / 30D Vol
1.54β · 89% Vol
Unified Composite Score
48.6
HOLD
Tech 29.0
Fund 55.0
Flow 63.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ENTX 1 – 3 EQ)
1. Valuation Multiples
EQ
Forward P/E
N/M
1.5x
Trailing P/E
N/M
1.5x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
8.1x
2. Growth & Scale
EQ
Revenue Growth (YoY)
-100.0%
-52.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$4.4M
Market Cap
$571.2M
$92.2M
3. Profitability & Quality
Tie
Gross Margin
N/A
100.0%
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-20.3%
-59.0%
4. Balance Sheet & Cash Flow
EQ
Cash Generation (TTM)
-$16M
-$20M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$265M Net Cash
$57M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
116.0% (33rd %ile)
261.3% (100th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ENTX (4) vs EQ (4)| Institutional Metric | ENTX | EQ | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $571.2M | $92.2M | ENTX | |
| Trailing P/E Ratio | N/M | 1.5x | EQ | |
| Forward P/E Ratio | N/M | 1.5x | EQ | |
| Revenue Growth (YoY) | -100.0% | -52.3% | EQ | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -20.3% | -59.0% | ENTX | |
| 52-Week Range Position | 73% ($1–$4) | 9% ($1–$4) | ENTX | |
| Beta / 30D Volatility | 0.92β · 53% Vol | 1.54β · 89% Vol | ENTX | |
| Unified Institutional Score | 47.5 / 100 (HOLD) | 48.6 / 100 (HOLD) | EQ | |
| Trailing 12M Revenue (USD) | N/A | $4.4M | Scale | |
| Gross Profit Margin (TTM) | N/A | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 8.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$16M ($265M Net Cash) | -$20M ($57M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ENTX +25.98 pp
3M Horizon
ENTX +48.46 pp
6M Horizon
ENTX +219.63 pp
1Y Horizon
ENTX +19.77 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENTX Revenue | EQ Revenue | ENTX Op. Margin | EQ Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $0M | N/A | -3059.7% | N/A | ENTX |
| FY2021 | $0M | N/A | -2139.6% | N/A | ENTX |
| FY2022 | $0M | $20M | -9714.2% | -393.9% | EQ |
| FY2023 | N/A | $40M | N/A | -40.2% | EQ |
| FY2024 | $0M | $40M | -5295.6% | -20.1% | EQ |
| FY2025 | $0M | N/A | -27450.0% | N/A | ENTX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ENTX
CONSOLIDATION
Current IV
116.0%
IV Percentile
33rd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EQ
UNCLASSIFIED
Current IV
261.3%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EQ Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ENTX vs EQ Key Questions & Quantitative Answers
As of Nov 20, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (47.5/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 4–4 (led by Options & Positioning), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. ENTX trades at $3.31 (N/M Forward P/E, 0.0% operating margin) versus EQ at $1.06 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-100.0% vs. -52.3% YoY). Technical & Structure Timing Caution: ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EQ leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENTX cumulative revenue shifted N/A while EQ shifted +100.0%. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.
EQ screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 8.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus EQ (-59.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.54β · 89% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EQ vs ENTX · Reverse Pair
ENTX vs IMMP
· Sector Peer
EQ vs ECOR
· Sector Peer
EQ vs CRVS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking